Isopropyl 1-benzoyl-4-benzo-yloxy-2,6-di-phenyl-1,2,3,6-tetrahydropyridine-3-carboxyl-ate.

In the title compound, C35H31NO5, the piperidine ring has an envelope conformation, with the phenyl-substituted C atom adjacent to the methyl-ene C atom as the flap. This flap atom deviates by 0.633 (2) Šfrom the mean plane of the other five essentially coplanar atoms in the ring (r.m.s. deviation = 0.044 Å). Intra-molecular C-H⋯O hydrogen bonds form S(7) and S(9) ring motifs. In the crystal, mol-ecules are linked by pairs of C-H⋯O hydrogen bonds, forming inversion dimers with R (2) 2(16) loops.

N-[(1E)-5-(3-Chloro-phen-yl)-3-methyl-cyclo-hex-2-en-1-yl-idene]hydroxyl-amine.

The whole of the title mol-ecule, C13H14ClNO, is disordered over two sets of sites with a refined occupancy ratio of 0.560 (6):0.440 (6). The oxime group having a C=N double bond adopts an E conformation. The dihedral angles between the rings (all atoms) are 89.5 (5) (major componenent) and 88.0 (6)° (minor component).

Dimethyl 2-(3-chloro-phen-yl)-6-hy-droxy-6-methyl-4-(methyl-amino)-cyclo-hex-3-ene-1,3-dicarboxyl-ate.

In the title compound, C(18)H(22)ClNO(5), the cyclo-hexene ring adopts a distorted half-chair conformation. The mol-ecular structure is stabilized by pairs of intra-molecular N-H⋯O and O-H⋯O inter-actions, generating S(6) motifs. In the crystal, the mol-ecules are linked by inter-molecular C-H⋯O inter-actions, forming centrosymmetric dimers.

Ethyl 4-(3-chloro-phen-yl)-3,6-dihydr-oxy-6-methyl-2-(2-pyrid-yl)-4,5,6,7-tetra-hydro-indazole-5-carboxyl-ate.

In the title compound, C(22)H(22)ClN(3)O(4), the cyclo-hexane ring adopts a twisted half-chair conformation. The mol-ecule is stabilized by an intra-molecular O-H⋯N inter-action, generating an S(6) motif. The crystal packing is stabilized by inter-molecular O-H⋯N and C-H⋯O inter-actions.

Synthesis, spectral and biological evaluation of some new thiazolidinones and thiazoles based on t-3-alkyl-r-2,c-6-diarylpiperidin-4-ones.

A stereospecific synthesis of some thiazolidinones and thiazoles was achieved conveniently through certain alpha-halo keto agents and reactivity of chloroacetyl chloride was successfully enhanced by CsF-Celite+CH(3)COONa. NMR studies revealed that the configuration of N-N bond is found to be anti with respect to C-3 alkyl group while C=N bond in thiazolidinone is trans with respect to N-N bond. Antimycobacterial activity tested against Mycobacterium tuberculosis indicated that compounds 19, 20, 24, 29, 30 and 32 exhibited twofold enhanced potency than Rifampicin. Similarly, antimicrobial screening studies pointed out that compounds 21 and 28 exceptionally noticed promising activities and particularly, 21 against Staphylococcus aureus and, 24 and 32 against Rhizopus sp. exhibited onefold elevated inhibition potency whereas 21 against Klebsiella pneumoniae showed twofold improved potency than Ciprofloxacin and Amphotericin B.

2,4-Bis(4-bromo-phen-yl)-3-aza-bicyclo-[3.3.1]nonan-9-one.

The title compound, C(20)H(19)Br(2)NO, shows a chair-chair conformation for the aza-bicycle with an equatorial disposition of the 4-bromo-phenyl groups [dihedral angle between the aromatic rings = 16.48 (3)°]. In the crystal, a short Br⋯Br contact [3.520 (4) Å] occurs and the structure is further stabilized by N-H⋯O hydrogen bonds and C-H⋯O inter-actions.

N-[4-Acetyl-5-(3-methoxy-phen-yl)-4,5-dihydro-1,3,4-thia-diazol-2-yl]acetamide.

The title compound, C(13)H(15)N(3)O(3)S, crystallizes with two mol-ecules in the asymmetric unit. The thia-diazole rings in both the mol-ecules adopt an envelope conformation. The crystal packing is stabilized by inter-molecular N-H⋯O and C-H⋯O inter-actions.